Bayer CropScience (506285) Q3 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 24/25 earnings summary
25 Aug, 2025Executive summary
Unaudited financial results for the quarter and nine months ended December 31, 2024, were approved and reviewed by the Board and auditors.
The business operates in a single segment, "Agri Care," and is subject to seasonality, making quarterly results not fully indicative of annual performance.
Financial highlights
Revenue from operations for the quarter ended December 31, 2024, was ₹10,569 million, up from ₹9,549 million year-over-year.
Profit before tax for the quarter was ₹336 million, down from ₹1,242 million year-over-year.
Net profit for the quarter was ₹342 million, compared to ₹931 million in the same quarter last year.
Earnings per share (EPS) for the quarter was ₹7.61, compared to ₹20.72 year-over-year.
Outlook and guidance
The company notes that its business is seasonal, and quarterly figures may not represent the full year's performance.
Latest events from Bayer CropScience
- Strong revenue and profit growth, boosted by a one-time gain from divestment.506285
Q1 26/27 - Revenue and net profit increased year-over-year, with robust cash flow and higher EPS.506285Q4 25/26
- Six-month net profit reached ₹4,314 million with a ₹90/share interim dividend declared.506285Q2 25/26
- Q1 FY25 net profit reached ₹2,542 million, with a ₹155 million impairment on Glyphosate assets.506285Q1 24/25
- Revenue up, but profit down on asset impairment; interim dividend of ₹90 per share declared.506285Q2 24/25
- FY25 revenue rose but net profit declined due to asset impairment; ₹35/share dividend proposed.506285Q4 24/25
- Five-year strategy targets EUR 25B+ sales, mid-20s margin, and clean audit for Q2 2025.506285Q1 25/26